Key result
ACE inhibitor use in children with metabolic syndrome was associated with statistically significant differences in glucose, insulin, HOMA-IR, LDL, HDL, and triglyceride levels at 12 months.
Why the study?
Does ACE inhibitor use improve insulin resistance and lipid profile in children over 10 years of age with obesity-associated metabolic syndrome?
Observational (n=53)
Does ACE inhibitor use improve insulin resistance and lipid profile in children over 10 years of age with obesity-associated metabolic syndrome?
ACE inhibitors may improve insulin resistance and hypertriglyceridemia in children with obesity-associated metabolic syndrome.
Answers are grounded in this paper and cite their sources.
May support ACE inhibitor use for metabolic parameters in obese children with metabolic syndrome; leaves open confirmation in randomized trials.
OBJECTIVE: The aim of this study was to evaluate the effects of using ACE inhibitors on insulin resistance, glucose metabolism, body fat composition, and lipid profile in children over 10 years of age with obesity-associated metabolic syndrome (MS). METHODS: A total of 53 children with MS, who had been followed for at least one year were included in the study. The sample was divided into two groups: Group 1-30 obese children (13 female, 17 male) who were not using an ACE inhibitor and Group 2-23 obese children (13 female, 10 male) who were using an ACE inhibitor. Anthropometric and laboratory data obtained at baseline and at the 3rd, 6th, and 12th months of follow-up were compared in the two groups. RESULTS: Comparison of the data in the two groups at 3rd, 6th, and 12th months revealed no statistically significant differences in terms of weight standard deviation score (SDS), body mass index SDS, weight for height percentile, body fat percentage, and very low-density lipoprotein (VLDL)values. However, there were statistically significant differences in mean glucose and insulin levels, homeostasis model assessment for insulin resistance, LDL and high-density lipoprotein values, and highly significant differences in mean triglyceride values. CONCLUSIONS: The positive effects of ACE inhibitor drugs, particularly on hypertriglyceridemia and insulin resistance, might bring them forth as first-line drugs in the treatment of obese and hypertensive children. Randomized, controlled, double-blind, and long-term studies are needed for a definitive conclusion.
No takes yet. Share an insight, caveat, or question.
Eda et al. (2013) conducted an observational in Obesity-associated metabolic syndrome (n=53). ACE inhibitors vs. No ACE inhibitor was evaluated on Insulin resistance, glucose metabolism, body fat composition, and lipid profile. ACE inhibitor use in children with metabolic syndrome was associated with statistically significant differences in glucose, insulin, HOMA-IR, LDL, HDL, and triglyceride levels at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: